|
|
|
|
|
terug |
Datum nieuwsfeit: 03-07-2007
Diatos rondt een ronde van serie D van 9,4 miljoen euro private financieringen af
( BW)(DIATOS-SA) Diatos Completes a Series D EUR 9.4 Million Private
Financing Round
Business Editors/Financial Editors/Medical Editors
PARIS--(BUSINESS WIRE)--July 3, 2007--Diatos SA, an international
biopharmaceutical company focusing on the research, development and
commercialization of targeted anti-cancer drugs, has announced the
successful closing of a financing round raising EUR 9.4 million. The
round was led by existing investors of Diatos including GIMV
(Belgium), Credit Agricole Private Equity (France), InterWest Partners
(United States), Innoven Partenaires (France), Sofinnova Partners
(France) and Biotech Fund Flanders (Belgium), also participated in the
round additional existing investors including AGF Private Equity
(France), NIF SMBC (Japan), Sopartec (Belgium), and SGAM (France).
This brings the total equity capital raised by Diatos since its
inception in 1999 to date to EUR 54.8 million.
The new injection of funding will allow Diatos to further develop
with full capacity its leading clinical products. The paclitaxel depot
formulated polymer gel DTS-301, having recently completed a Phase IIa
and poised to enter Phase IIb/III in Esophageal cancer, the
doxorubicin prodrug DTS 201, having recently completed a Phase I in
solid tumors and poised to enter Phase II; as well as to robustly
expand its product pipeline with the launch of DTS-108, a promising
second generation Irinotecan, in GLP preclinical toxicology studies
and the continuous focus on generating new TSP-based drugs.
Commenting on the financing, Dr John Tchelingerian, President and
CEO said:
"We are delighted to have received this significant financial
support from our world class investor group that continuously
supported Diatos and its management team. The Company is now in a
strong financial position with a deep and balanced portfolio of
oncology products and assets. With this financing we will focus on
taking our clinical and preclinical products forward to their next
stage of maturity and achieve significant development and value
creation milestones".
About Diatos
Diatos is a biopharmaceutical company dedicated to the research,
development and commercialization of innovative anti-cancer drugs with
enhanced tumor targeting or improved biodistribution. Diatos is
expanding its portfolio of drug candidates with new compounds that
utilize its Vectocell(R) delivery technology or its Tumor-Selective
Prodrug (TSP) technology as well as with in-licensed candidate and
marketed cancer therapies. Diatos is headquartered in Paris, France
and operates subsidiaries in Belgium and the United States of America.
About Diatos' Portfolio
-- DaunoXome(R), a liposomal formulation of widely used cancer
drug daunorubicin, improves the biodistribution of
daunorubicin and fosters its sustained release in the blood,
which potentially allows the administration of higher doses
than with non-liposomal formulations. DaunoXome is marketed in
Kaposi's sarcoma and is being re-launched in acute leukaemia
in Europe. DaunoXome was in-licensed from Gilead Sciences,
Inc.
-- DTS-301, a paclitaxel depot formulation in the polymer gel
ReGel(R), releases paclitaxel, a widely used cancer drug,
directly to the tumor site, avoiding systemic side effects.
DTS-301 is in Phase II clinical stage and was in-licensed from
Protherics PLC.
-- DTS-201, a doxorubicin prodrug, increases the concentration of
doxorubicin, a widely used cancer drug, at the tumor site by
means of a reactivation mechanism specific to the tumor
environment. DTS-201 has completed Phase I clinical studies in
Belgium and France in Q2-07. Exclusive European rights for
DTS-201 were in-licensed from Medarex Inc.
-- DTS-108 is a prodrug of SN-38, the active metabolite of the
widely-used cancer drug irinotecan, and is based on Diatos'
Vectocell(R) technology. DTS-108 aims to increase the efficacy
of SN-38 while reducing the toxic effects of irinotecan.
DTS-108 is in preclinical development.
For further information please visit the website at www.diatos.com
About AGF Private Equity - www.agpe.com
AGF Private Equity, a subsidiary of the AGF Insurance Company,
member of the Allianz Group, is specialized in non-listed investments.
The company manages an investment portofolio close to EUR 1,7Bn, is
among the leaders in France in managing funds of funds, and is also
one of the most active investors in Venture Capital. The Venture
Capital team has invested in 50 high tech companies. AGF Private
Equity invests EUR 30 M each year in innovative firms. With close to
EUR 300 M under management in its Venture Capital activity, AGF
Private Equity is an active partner of growth companies.
About Credit Agricole Private Equity -
http://www.ca-privateequity.com
Credit Agricole Private Equity is an AMF-accredited asset
management subsidiary of Credit Agricole S.A., specialising in private
equity investment in non-listed companies across a range of
industries. A team of 40 investors operating in several areas
(Later-Stage Financing & LBO, Venture Capital, Secondary Market,
Mezzanine, Renewable Energies, PPP Infrastructure, liquidity
solutions, etc.), manages EUR 1.5 billion through venture and
innovation funds.
About GIMV - www.gimv.com
GIMV is a Belgian investment company. It was established in 1980,
and since 1997, it has been quoted on Euronext Brussels. Its purpose
is to invest in the equity of unlisted companies (private equity).
GIMV operates in three areas. GIMV's venture capital is invested
primarily in ICT and Life Sciences. In more traditional industries it
also undertakes management buy-outs (MBOs) and it provides growth
capital (Corporate Investment). The portfolio maintains a balance
among start-up companies, fast growth companies and major enterprises.
In this way, GIMV positions itself as a player on the international
market.
About Innoven Partenaires - www.innoven-partners.com
Innoven Partenaires is an independent asset management company
authorised by the Autorite des Marches Financiers to manage venture
capital FCPI funds (Fonds Commun de Placements dans l'Innovation).
Founded in 1997, Innoven Partenaires currently manages 210 MEUR via 15
FCPI funds, 7 of which are managed on behalf of La Poste (the French
Post Office). Innoven Partenaires invests in France and across Europe
in young companies with high growth potential in the life sciences,
information technology, communications and energy / cleantech sectors.
The investment team has a pro-active approach, working closely with
portfolio companies, making available a broad international network,
in-depth mergers and acquisitions and business development experience
and a strong track record in bringing companies to IPO.
About InterWest Partners - www.interwest.com
InterWest Partners (www.interwest.com), founded in 1979, is a
leading diversified venture capital firm focused on building long-term
relationships with entrepreneurs and portfolio companies. With more
than $2 billion of capital raised, including its new investment fund
of $600 million, InterWest has 11 experienced partners in Menlo Park,
CA and Dallas, TX, who bring together deep domain knowledge in life
sciences and information technology. InterWest Partners has
consistently helped grow some of the most influential companies in
information technology and life sciences. The firm's investments in
life sciences include: ArthroCare (ARTC), Cor Therapeutics (CORR;
acquired by Millennium Pharmaceuticals, MLNM), Corgentech (CGTK),
Corixa (CRXA), Coulter Pharmaceutical (CLTR; acquired by Corixa
Pharmaceuticals, CRXA; acquired by GlaxoSmithKline PLC, GSK), Cubist
Pharmaceuticals (CBST), Epicor Medical (acquired by Saint Jude
Medical, STJ) Inspire Pharmaceuticals (ISPH), Myogen (MYOG), Spinal
Dynamics (acquired by Medtronic, MDT), TheraSense (THER; acquired by
Abbott Labs, ABT) and Ventritex (VNTX; acquired by St. Jude Medical,
STJ).
About NIF SMBC - www.nifsmbc.co.jp
On October 1, 2005, NIF Ventures (Daiwa Securities Group) and SMBC
Capital (Sumitomo Mitsui Financial Group) merged to form NIF SMBC
Ventures. NIF SMBC Ventures, the newly-created venture capital
company, formed by integrating these two precursors, will not only
secure a comprehensive business network, but also establish an
outstanding service structure that integrates expertise in the entire
business processes of finding investment targets, listing their
stocks, and ultimately carrying out mergers and acquisitions. NIF SMBC
Ventures has taken the first step for further growth as a private
equity house and will continue to contribute to society by creating
new industries through the finding and development of promising
unlisted companies.
About SGAM - www.sgam.com
Societe Generale Asset Management is one of the world's leading
asset managers with EUR 371.2bn of assets under management as at 31
March 2007. A subsidiary of the Societe Generale Group, SGAM is a
global player with a balanced and robust business model based on:
- its multi-centre structure: 2,830 employees, including 670
managers and analysts, are located at the heart of the markets in
Europe, the United States and Asia;
- a business that covers all asset classes: equities, fixed
income, balanced, and alternative investment where SGAM is among the
leaders with EUR 67 bn in assets under management;
- access to all types of investor: institutions, distributors,
corporates and individuals, all of whom benefit from SGAM's leading
edge expertise and a local service. Thanks to cross-selling and a
focus on quality and constant innovation, SGAM has developed
value-added management solutions tailored to clients' specific needs
and which optimize performance and control risk. SGAM is rated M2 by
Fitch Ratings, thus retaining since 2000 the top rating awarded to an
asset management company for the whole of its international structure
About Sofinnova Partners - www.sofinnova.fr
Founded in Paris in 1972, Sofinnova Partners is one of Europe's
leading independent venture capital firms. With EUR 900 million under
management, Sofinnova Partners invests in start-ups and early-stage
companies in information technology and life sciences. Its investment
strategy consists of investing early in teams and projects with high
potential, most often acting as lead or co-lead investor. Sofinnova
Partners also benefits from a long-established relationship with its
sister company in San Francisco, Sofinnova Ventures. Sofinnova
Partners' teams consist of 10 professionals who bring valuable market
insight and technical expertise to portfolio companies.
About Sopartec - www.sopartec.com ; www.vivesfund.com
SOPARTEC is the investment and technology transfer company of the
Universite Catholique de Louvain (UCL). SOPARTEC has been entrusted
with the management of the intellectual property of the university and
its commercialization through licenses, partnerships and the creation
of new companies. In particular, SOPARTEC has invested and
participated in the creation of more than 20 spin-off companies based
in whole or in part on research results from UCL, such as Ion Beam
Application (IBA). SOPARTEC is also the managing company of VIVES, a
EUR 15 mio seed capital fund financed by EIF, KBC, Fortis, Sofina,
Nivelinvest and SOPARTEC. The goal of VIVES is to stimulate the
creation and growth of university spin-offs and invest in existing
young technology companies with which a strategic partnership can be
concluded.
--30--RB/lo*
CONTACT: Media
Northbank Communications for Diatos
Katja Stout / Dr Christelle Kerouedan / Justine Lamond
diatos@northbankcommunications.com
English enquiries phone: +44 (0)20 7268 3242
French enquieres phone: +44 (0)20 7268 3235
or
Investors
Diatos
Dr John Tchelingerian, President & CEO
+ 33 (0)1 53 80 93 81
Jtchelingerian@Diatos.com
Disclaimer: Deze bekendmaking is officieel geldend in de originele
brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten
worden vergeleken met de tekst in de brontaal welke als enige,
juridische geldigheid beoogt.